



**Bharat Immunologicals & Biologicals Corporation  
Limited  
BIBCOL**

**Bharat Immunologicals & Biologicals Corporation**

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

*Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203*

*Phone (09458096110), Tele Fax -05732 238757*

*Email – [sklalacs@yahoo.co.in](mailto:sklalacs@yahoo.co.in) Website- [www.bibcol.com](http://www.bibcol.com)*

No.BIB/CS/SE/UAFR-Q2/2020-21

Date 30.12.2020

To  
The Listing Department  
Bombay Stock Exchange  
Phiroze jeejeebhoy Tower  
25, Dalal Street, Mumbai – 400001

**Sub: Submission of Unaudited Quarterly Financial Results for the quarter and half  
year ended September 2020 as Compliance of LODR 2015**

Sir/Madam,

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter and half year ended September 2020 approved by the Board of the Company in its Meeting on 30.12.2020.

The XBRL form available at bse site is not working for filing, on availability of working form at bse it will be filed in XBRL as per the requirement of Exchange.

Submitted please.

Thanking you,

**For BHARAT IMMUNOLOGICAL AND BIOLOGICAL  
CORPORATION LIMITED (BIBCOL)**

Sandip Kumar Lal  
(General Manager/Company Secretary)

**Part I**  
**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER AND SIX MONTHS ENDED**  
**30-09-2020**  
**Selected Information for the Period Ended 30-09-2020**

(INR in Lakh)

S.No	Particulars	3 Months Ended on 30-09-2020	Preceding 3 Months Ended on 30-06-2020	Corresponding 3 Months Ended in the previous year 30-09-2019	Half Year Ended on 30-09-2020	Previous Year Ended as on 31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>INCOME</b>					
	a) Income from Operations	2,535.83	1,915.29	810.13	4,451.12	6,683.65
	b) Other Income	13.75	-58.17	17.45	-44.42	118.37
	<b>Total Revenue (1)</b>	<b>2,549.58</b>	<b>1,857.12</b>	<b>827.58</b>	<b>4,406.70</b>	<b>6,802.02</b>
2	<b>EXPENDITURE</b>					
	a) Cost of Material Consumed	1,981.51	2,141.45	4,452.63	4,122.96	6,895.34
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	343.38	-760.94	-3,428.87	-417.56	-1,299.07
	d) Employees Benefits	346.93	158.49	255.14	505.42	1,137.25
	e) Finance Cost	116.60	109.10	124.68	225.70	474.17
	f) Depreciations and Amortisation Expense	5.92	5.92	5.76	11.84	23.67
	g) Other Expense	313.77	313.45	200.52	627.22	990.99
	<b>Total Expense (2)</b>	<b>3,108.11</b>	<b>1,967.47</b>	<b>1,609.86</b>	<b>5,075.58</b>	<b>8,222.34</b>
3	Profit/ (Loss) before exceptional items (1-2)	-558.53	-110.35	-782.28	-668.88	-1,420.32
4	Tax Expense				-	-
	a) Current Tax	-	-	-	-	-
	b) Deferred Tax	-171.91	-31.90	-216.37	-203.81	-399.19
5	<b>Profit/ (Loss) from continuing Operations (3-4)</b>	<b>-386.62</b>	<b>-78.45</b>	<b>-565.91</b>	<b>-465.07</b>	<b>-1,021.13</b>
6	Other Comprehensive Income/(Loss) (Net of Taxes)	-	-	13.05	-	0.77
7	Total Comprehensive Income/ (Loss) for the period (5+6)	-386.62	-78.45	-552.86	-465.07	-1,020.36
8	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00	4,318.00
9	Earning Per Share (of INR 10/- each) not annualised				-	-
	a) Basic	-0.90	-0.18	-1.28	-1.08	-2.36
	b) Diluted	-0.90	-0.18	-1.28	-1.08	-2.36

Note:- Refer our Note Separately

*Sip.*      *RJ*

Part II						
Selected Information for the Period Ended 30-09-2020						
S.No	Particulars	3 Months Ended on 30-09-2020	Preceding 3 Months Ended on 30-06-2020	Corresponding 3 Months Ended in the previous year 30-09-2019	Half Year Ended on 30-09-2020	Previous Year Ended as on 31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	<b>PARTICULARS OF SHAREHOLDING</b>					
	Public shareholding					
	- Number of Shares	175,94,000.00	175,94,000.00	175,94,000.00	175,94,000.00	175,94,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding					
	a) Pledged/ Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-	-
	b) Non - encumbered					
	- Number of Shares	255,86,000.00	255,86,000.00	255,86,000.00	255,86,000.00	255,86,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25
<b>B</b>	<b>Particulars</b>	<b>3 Months ended (30/09/2020)</b>				
	<b>INVESTOR COMPLAINTS</b>					
	Pending at the beginning of the quarter	-				
	Received during the quarter	-				
	Disposed of during the quarter	-				
	Remaining unresolved at the end of the quarter	-				

S. Srip.

R. R.

**Segment Reporting for the Period Ended 30-09-2020**

(INR in Lakh)

S.No	Particulars	3 Months Ended on 30-09-2020	Preceding 3 Months Ended on 30-06-2020	Corresponding 3 Months Ended in the previous year 30-09-2019	Half Year Ended on 30-09-2020	Previous Year Ended as on 31-03-2020
1	<b>SEGMENT REVENUE</b>					
	Oral Polio Vaccine	2,533.57	1,912.00	810.13	4,445.57	6,683.42
	Zinc Dispersible Tablets	0.03	0.13	-	0.16	0.23
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	2.23	3.16	-	5.39	-
	Less: Inter segment revenue	-	-	-	-	-
	<b>Net Sales/ Income from operations</b>	<b>2,535.83</b>	<b>1,915.29</b>	<b>810.13</b>	<b>4,451.12</b>	<b>6,683.65</b>
2	<b>SEGMENT RESULTS (Profit Before Tax)</b>					
	Oral Polio Vaccine	555.49	109.90	-782.28	-665.39	-1,410.59
	Zinc Dispersible Tablets	-2.16	-1.01	-	-3.17	-9.73
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	-0.88	0.56	-	-0.32	-
	Less: Un allocable expenditure net off un allocable Income	-	-	-	-	-
	<b>Total Profit before Tax</b>	<b>558.53</b>	<b>110.35</b>	<b>-782.28</b>	<b>-668.88</b>	<b>1,420.32</b>
3	<b>CAPITAL EMPLOYED (Segment Assets less Liabilities)</b>					
	Oral Polio Vaccine	4,373.51	4,829.87	1,939.69	4,373.51	914.05
	Zinc Dispersible Tablets	228.56	226.40	-205.65	-228.56	-8.72
	BIB Sweet Tablets	0.03	0.03	0.03	0.03	0.03
	BIBSANIT	-	-	-	-	-
	Others	-0.38	-0.38	218.67	-0.38	-51.85
	<b>Total Capital employed</b>	<b>4,144.60</b>	<b>4,603.12</b>	<b>1,952.74</b>	<b>4,144.60</b>	<b>853.51</b>

*S. Dip.*

*[Signature]*

**Statement of Assets and Liabilities as at 30th September, 2020**

Particulars		As at 30th September, 2020	As at 31st march, 2020
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	434.67	446.51
	(b) Capital work-in-progress	21.93	21.93
	(c) Financial Assets	1,155.37	1,363.32
	(d) Other non-current assets	50.79	51.50
	(e) Non Current Tax Assets (Net)	82.74	97.96
	(f) Deferred tax assets (net)	1,603.62	1,399.75
		<b>3,349.13</b>	<b>3,380.97</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	3,302.63	5,171.89
	(b) Financial Assets		
	(i) Investments		
	(ii) Trade receivables	1,653.07	1,761.38
	(ii) Cash and cash equivalents	105.55	98.50
	(iii) Bank balances other than (ii) above	896.37	1,111.34
	(c) Other current assets	1,297.96	1,158.90
		<b>7,255.58</b>	<b>9,302.01</b>
		<b>10,604.71</b>	<b>12,682.98</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity Share capital	4,318.00	4,318.00
	(b) Other Equity	(2,735.68)	(2,270.62)
		<b>1,582.32</b>	<b>2,047.38</b>
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Deferred Grant	-	-
	(b) Long Term Provisions	564.85	564.85
		<b>564.85</b>	<b>564.85</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	4,303.75	303.84
	(ii) Trade payables	2,420.20	4,353.15
	(iii) Other Financial Liabilities	36.24	38.24
	(b) Deferred Grant	-	-
	© Short Term Provisions	282.80	87.91
	(d) Other Current liabilities	1,414.55	5,287.61
		<b>8,457.53</b>	<b>10,070.75</b>
		<b>10,604.71</b>	<b>12,682.98</b>

S. 04.

*[Signature]*

Cash flow statement, indirect		
Particulars		6 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2020
B	Date of end of reporting period	30-09-2020
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
Part I	Blue colour marked fields are non-mandatory.	
<b>Statement of cash flows</b>		
Whether cash flow statement is applicable on company		Yes
<b>Cash flows from used in operating activities</b>		
Profit before tax		-558.53
<b>Adjustments for reconcile profit (loss)</b>		
Adjustments for finance costs		225.700
Adjustments for decrease (increase) in inventories		1869.260
Adjustments for decrease (increase) in trade receivables, current		108.308
Adjustments for decrease (increase) in trade receivables, non-current		0.000
Adjustments for decrease (increase) in other current assets		-139.056
Adjustments for decrease (increase) in other non-current assets		15.926
Adjustments for other financial assets, non-current		207.948
Adjustments for other financial assets, current		0.000
Adjustments for other bank balances		0.000
Adjustments for increase (decrease) in trade payables, current		-1932.953
Adjustments for increase (decrease) in trade payables, non-current		0.000
Adjustments for increase (decrease) in other current liabilities		-3873.063
Adjustments for increase (decrease) in other non-current liabilities		0.000
Adjustments for depreciation and amortisation expense		11.840
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss		0.000
Adjustments for provisions, current		194.894
Adjustments for provisions, non-current		0.004
Adjustments for other financial liabilities, current		-2.003
Adjustments for other financial liabilities, non-current		0.000
Adjustments for unrealised foreign exchange losses gains		0.000
Adjustments for dividend income		0.000
Adjustments for interest income		-37.320
Adjustments for share-based payments		0.000
Adjustments for fair value losses (gains)		0.000
Adjustments for undistributed profits of associates		0.000
Other adjustments for which cash effects are investing or financing cash flow		0.000
Other adjustments to reconcile profit (loss)		0.000
Other adjustments for non-cash items		0.000

S. S. S.

R. R.

Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.000
<b>Total adjustments for reconcile profit (loss)</b>	<b>-3350.515</b>
<b>Net cash flows from (used in) operations</b>	<b>-4019.395</b>
Dividends received	
Interest paid	0.000
Interest received	0.000
Income taxes paid (refund)	0.000
Other inflows (outflows) of cash	
<b>Net cash flows from (used in) operating activities</b>	<b>-4019.395</b>
<b>Cash flows from used in investing activities</b>	
Cash flows from losing control of subsidiaries or other businesses	0.000
Cash flows used in obtaining control of subsidiaries or other businesses	0.000
Other cash receipts from sales of equity or debt instruments of other entities	0.000
Other cash payments to acquire equity or debt instruments of other entities	0.000
Other cash receipts from sales of interests in joint ventures	0.000
Other cash payments to acquire interests in joint ventures	0.000
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.000
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.000
Proceeds from sales of property, plant and equipment	0.000
Purchase of property, plant and equipment	0.000
Proceeds from sales of investment property	0.000
Purchase of investment property	0.000
Proceeds from sales of intangible assets	0.000
Purchase of intangible assets	0.000
Proceeds from sales of intangible assets under development	0.000
Purchase of intangible assets under development	0.000
Proceeds from sales of goodwill	0.000
Purchase of goodwill	0.000
Proceeds from biological assets other than bearer plants	0.000
Purchase of biological assets other than bearer plants	0.000
Proceeds from government grants	0.000
Proceeds from sales of other long-term assets	0.000
Purchase of other long-term assets	0.000
Cash advances and loans made to other parties	0.000
Cash receipts from repayment of advances and loans made to other parties	0.000
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.000
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.000
Dividends received	0.000

S. S. S.

R. R.

Interest received	37.320
Income taxes paid (refund)	0.000
Other inflows (outflows) of cash	0.000
<b>Net cash flows from (used in) investing activities</b>	<b>37.320</b>
<b>Cash flows from used in financing activities</b>	
Proceeds from changes in ownership interests in subsidiaries	0.000
Payments from changes in ownership interests in subsidiaries	0.000
Proceeds from issuing shares	0.000
Proceeds from issuing other equity instruments	0.000
Payments to acquire or redeem entity's shares	0.000
Payments of other equity instruments	0.000
Proceeds from exercise of stock options	0.000
Proceeds from issuing debentures notes bonds etc	0.000
Proceeds from borrowings	3999.909
Repayments of borrowings	0.000
Payments of finance lease liabilities	0.000
Payments of lease liabilities	0.000
Dividends paid	0.000
Interest paid	225.700
Income taxes paid (refund)	0.000
Other inflows (outflows) of cash	0.000
<b>Net cash flows from (used in) financing activities</b>	<b>3774.209</b>
<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>-207.866</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	
Effect of exchange rate changes on cash and cash equivalents	
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-207.866</b>
Cash and cash equivalents cash flow statement at beginning of period	1209.840
<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>1001.92</b>

### Notes to the Results

1. The above Un-Audited results for the Quarter ended 30th September, 2020 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in their meeting held on December 30, 2020.
2. Valuation of Closing Stock has been done on the basis of IND AS-2.
3. Depreciation has been charged on the basis of Companies Act 2013
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year ended 30th September, 2020.

*S. S. P.*

*R. P.*

7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As compliant corresponding figures in the previous year have been subjected to review / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS as given below: For Table, kindly refer Corporate Announcements on [www.bseindia.com](http://www.bseindia.com).
10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

(Chandra Prakash Goyal)  
Managing Director

Date :- 30.12.2020

S. Dip.

